Immunotherapy has emerged as a promising treatment paradigm for many malignancies
and is transforming the drug development landscape. Although immunotherapeutic agents …

Cellular interactions in the tumor microenvironment (TME) significantly govern cancer
progression and drug response. The efficacy of clinical immunotherapies has fostered an …

Cancer metastasis is no longer viewed as a linear cascade of events but rather as a series
of concurrent, partially overlapping processes, as successfully metastasizing cells assume …

Immunotherapy has revolutionized cancer therapy, largely attributed to the success of
immune-checkpoint blockade. However, there are subsets of patients across multiple …

Metastatic melanoma is challenging to manage. Although targeted-and immune therapies
have extended survival, most patients experience therapy resistance. The adaptability of …

Background Tumor progression is accompanied by dramatic remodeling of the surrounding
extracellular matrix leading to the formation of a tumor-specific ECM, which is often more …

Immunotherapy is revolutionizing cancer treatment; however, complete responses are
achieved in only a small fraction of patients and tumor types. Thus, there is an urgent need …

Specific mechanisms by which tumor-infiltrating lymphocytes (TIL) become dysfunctional
remain poorly understood. Here, we employed a two-pronged approach using single-cell …

The identification of patient-specific tumor antigens is complicated by the low frequency of T
cells specific for each tumor antigen. Here we describe NeoScreen, a method that enables …

The use of existing mouse models in cancer research is of utmost importance as they aim to
explore the casual link between candidate cancer genes and carcinogenesis as well as to …